Photo by Cosmin Andrei Buzamat / Unsplash. Illustrative stock photograph.
Evidence checked: October 4, 2026. Prepared with AI assistance and reviewed and approved for publication by David L. Carpenter, BSN, RN.
At first, the scale moved regularly. Now it keeps returning to roughly the same number, even though you are still taking your medication. It is easy to wonder whether you have done something wrong—or whether treatment has stopped helping.
A slowdown deserves context before it becomes a reason to overhaul your routine. Weight loss can level off during continued treatment, but that does not explain every stall or rule out a problem. This article focuses on adults using Wegovy or Zepbound injections and on preparing for a useful clinician visit. [1] [2]
A plateau is a pattern, not one disappointing weigh-in
The word “plateau” sounds precise, but people use it in different ways. A few similar readings at home are not automatically equivalent to the plateau measured in a clinical trial.
An exploratory analysis of the SURMOUNT-1 and SURMOUNT-4 tirzepatide trials defined a plateau as less than 5% weight change over a 12-week interval and all later intervals. SURMOUNT-4 included one 16-week interval because of its visit schedule. This definition allowed some continued loss; it did not mean the scale was completely motionless. [2]
This was a research definition, not an instruction to wait 12 weeks before asking for help. If the trend concerns you, you can discuss it sooner.
For useful home comparisons, NHS England recommends a consistent weighing time, preferably morning, at regular weekly-to-monthly intervals. Use the same scale on a firm, level surface and similar clothing. [3] If you work nights, discuss a consistent time that fits your sleep schedule. If weighing worsens anxiety or disordered eating, ask your care team for a monitoring approach that supports your wellbeing.
What the medication studies actually show
STEP 5 randomized 304 adults without diabetes who had obesity, or overweight plus a weight-related condition. Half received weekly semaglutide 2.4-mg injections and half received placebo; both groups had behavioral support. Weight loss in the semaglutide group appeared to level off around week 60 and was maintained through week 104. The estimated average reduction from starting weight at week 104 was 15.2%, versus 2.6% with placebo. This analysis included all randomized participants, accounting for treatment discontinuation and missing measurements. [1]
Those are group averages, not a personal deadline or promised result. Participants were predominantly white and female, limiting generalizability. The study tested a specific injectable regimen; it should not be treated as evidence for every formulation or dose.
The tirzepatide analysis examined existing trial data after the fact. It included selected participants who received at least 75% of study doses, lost at least 5% by the endpoint, reached the required dose by week 24, had no subsequent dose reduction, and had an endpoint weight measurement. It therefore does not represent everyone who starts treatment. It did not test what to do after a plateau or establish a dose-changing strategy. [2]
Neither study supports diagnosing medication tolerance—meaning reduced responsiveness to a medicine—from a flat stretch on the scale alone.
Why weight loss can slow
Weight change involves interacting biological and behavioral processes. As weight falls, energy expenditure and appetite can change. Researchers use models to explore how those changes could contribute to slowing weight loss; a model cannot diagnose why an individual’s weight has stalled. [4]
A 2024 study by Kevin Hall used a mathematical model fitted to average trajectories from studies of dietary restriction, semaglutide, tirzepatide, and gastric bypass. The model suggested that medication and surgery can weaken appetite feedback and extend the weight-loss phase, while plateaus can still occur. [4]
This is a proposed explanation based on modeling fitted to group data. It is not a direct measurement of your metabolism, a test for tolerance, or proof that a particular food or workout will restart weight loss. A plateau does not establish that your metabolism is “broken.”
Prepare a useful snapshot before your appointment
Rather than changing several things at once, gather information your prescriber can use. The following is a practical appointment aid, not a validated plateau treatment.
Start with your timeline. Note when treatment began, your starting weight, the recent trend, and when you first noticed the slowdown. Include the medication and prescribed dose you currently use, plus any missed doses or supply interruptions. If you are unsure about storage or injection technique, write that down for your pharmacist.
Next, describe an ordinary week. What does a workday look like compared with a day off? Are meals regularly interrupted? Are you skipping food because you feel too full, or struggling to find tolerable options? Has walking or strength work changed because of pain, fatigue, overtime, or caregiving?
Include symptoms in plain language. “I can manage breakfast but feel nauseated by lunchtime” gives your clinician more to work with than “the medicine is not working.” Mention changes in bowel habits, appetite, sleep, and any new medicines or supplements.
A short note is enough. You do not need a perfect spreadsheet, exhaustive calorie log, or wearable device to have a useful conversation.
Review the plan without turning it into punishment
A stall is not a reason to assume that eating as little as possible is the next step. It is a reason to ask whether your existing plan still fits your needs and circumstances.
Ask a registered dietitian or prescriber whether your nutrition needs are being met and symptoms are interfering. Bring examples of difficult workdays and days off. For meal ideas and low-appetite guidance, use the related HCW reading below; this article’s purpose is to organize the plateau discussion, not provide another meal plan.
For movement, describe what you can comfortably repeat and what you would like to improve. You might want a manageable walking routine, help adapting strength exercises, or a plan that survives a week of night shifts. Avoid treating a harder workout as a guaranteed plateau cure.
Choose a change with your care team, agree on what you will observe, and set a follow-up point. That makes the plan easier to evaluate than changing food, exercise, supplements, and medication all at once.
Do not use the scale to set your dose
Do not use a plateau as a reason to raise your dose, take injections closer together, add another weight-loss medicine, or take a “drug holiday” on your own. Follow the instructions for your prescribed product. For missed doses or a longer interruption, check its specific instructions and ask your prescriber or pharmacist if you are unsure how to proceed; there is no single restart rule for both medicines. Serious symptoms need the separate action described below. [5] [6]
Medication decisions involve benefit, side effects, other health conditions, other medicines, and affordability. NIDDK describes continued treatment as an option when weight loss improves health and serious side effects are absent. That is a general principle, not a personal instruction to continue. Maintaining an improvement is different from never having responded; your prescriber can help distinguish them. [7]
Ask your clinician: Are we still pursuing additional loss, maintaining a meaningful improvement, or reconsidering treatment because the benefit is insufficient? The answer should reflect your health, not a comparison with someone else’s social-media results.
Symptoms that should not wait for a plateau review
Contact your prescriber promptly for nausea, vomiting, or diarrhea that persists, difficulty keeping fluids down, or severe or persistent stomach problems. Both medication guides warn that fluid loss can lead to dehydration and kidney problems. [5] [6] Reduced urination or worsening dizziness also warrants attention; get medical help immediately for confusion, fainting, or no urination. [8]
Severe abdominal pain that persists, sometimes spreading to the back, with or without nausea or vomiting, can signal pancreatitis. Both Medication Guides instruct patients with these symptoms to stop using the medicine and contact a healthcare professional immediately. Seek urgent evaluation; use emergency care if you feel seriously ill or cannot obtain prompt help. This warning is different from changing medication to address a plateau. [5] [6]
Five questions to take to your prescriber
- Does my recent trend look like expected slowing, maintenance, or an inadequate response?
- Which health outcomes should we track alongside weight?
- Could side effects, treatment interruptions, or another medicine be affecting the plan?
- Would nutrition support or an adapted activity plan help me meet my needs?
- What should we keep doing, what should we change, and when should we reassess?
You do not need to prove that you have tried hard enough before asking these questions. Bring an honest picture of your routine and symptoms. The aim is a plan you can understand, tolerate, and sustain—not a race to make every weigh-in lower than the last.
General educational information only; not individualized medical advice. Persistent symptoms or difficulty eating and drinking deserve attention even when weight is still falling.
Evidence limitations
STEP 5 was manufacturer-funded, predominantly White and female, and tested one injectable regimen; its results are group estimates. The manufacturer-associated tirzepatide analysis excluded less-adherent participants and nonresponders. Its January 22, 2025 correction changed “week 72%” to “week 72.” Hall’s work is modeling, not a trial of plateau treatment. No evidence here establishes that the appointment checklist or a particular lifestyle change reverses a plateau.
Sources
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083–2091. DOI: 10.1038/s41591-022-02026-4. PMID: 36216945. Results cited use the treatment-policy analysis. Read source.
- Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity. 2025;15:e12734. DOI: 10.1111/cob.12734. PMID: 39800653. Corrected publisher text checked. Read source.
- NHS England. How to Record Your Weight. Official patient leaflet, publication reference PRN00916. PDF directly checked October 4, 2026. Read source.
- Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity. 2024;32:1163–1168. Read source.
- Eli Lilly. Zepbound US Prescribing Information and Medication Guide. Revised August 2026; checked October 4, 2026. Sections 2.3, 5.2, 5.3, 5.5 and patient Medication Guide. Read source.
- Novo Nordisk. Wegovy Prescribing Information and Medication Guide. Revised June 2026; checked October 4, 2026. Injection-specific instructions, section 2.4; warnings 5.2, 5.5 and 5.6; injection Medication Guide. Read source.
- NIDDK. Prescription Medications to Treat Overweight & Obesity. Used for general long-term treatment principles, not a current inventory of approved medicines. Read source.
- MedlinePlus. Dehydration. US National Library of Medicine. Symptoms and urgent warning signs; accessed October 4, 2026. Read source.
Questions or feedback?
For a private message, email David at contact@healthcontentworks.com. The comment form below is for public discussion. Please do not include private medical details in comments.
Leave a Reply